Akebia Therapeutics, Inc. (AX9.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
As of 08:00AM CEST. Market open.
| Previous Close | 1.2660 |
| Open | 1.3360 |
| Bid | 1.3810 x 30000 |
| Ask | 1.3950 x 30000 |
| Day's Range | 1.3360 - 1.3360 |
| 52 Week Range | 0.7410 - 2.8500 |
| Volume | |
| Avg. Volume | 534 |
| Market Cap | 306.357M |
| Beta (5Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2600 |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.54 |
PR NewswireAkebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, prior to the open of financial markets.
- PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 10 newly-hired employees options to purchase an aggregate of 41,000 shares of Akebia's common stock on April 30, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Simply Wall St.When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
With the business potentially at an important milestone, we thought we'd take a closer look at Akebia Therapeutics...
© 2024 Yahoo. All rights reserved.